# Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Study · id `cardio:ct-nct01505790` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01505790](<https://clinicaltrials.gov/study/NCT01505790>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01505790

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

## Technical summary

Registry record NCT01505790. Randomized; no masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 187 participants (enrolled count; ClinicalTrials.gov record NCT01505790, source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)
- Start date: 2011-07 (registry gives no type) (ClinicalTrials.gov record NCT01505790, source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01505790, source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)
- Completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01505790, source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT01505790, source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01505790-2012-05-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
- Condition: Acute Coronary Syndromes
- Intervention (Drug): PRASUGREL
- Intervention (Drug): Clopidogrel
- Lead sponsor: Assistance Publique Hopitaux De Marseille
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Assistance Publique Hopitaux De Marseille (`cardio:org-assistance-publique-hopitaux-de-marseille`)

## Provenance

Content hash: 5db70b76afb9657190baf959a26a5c8a8113c128613ce6ee9364fdd20117e037
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
